Share
March 12, 2020 "Italy will participate in the two phase III studies promoted by Gilead Sciences to evaluate the efficacy and safety of the experimental molecule Remdesivir in hospitalized adults diagnosed with Covid-19".This was announced by the American company, stating that "the studies will initially be conducted at the Sacco hospital in Milan, the Policlinico San Matteo in Pavia, the hospital in Padua, the university hospital in Parma and the National Institute of infectious diseases Lazzaro Spallanzani of Rome ".
"In collaboration with Aifa (Italian Medicines Agency), other centers in regions with high incidence of coronavirus infection are being identified for inclusion in the studies. Remdesivir - Gilead recalls - is not yet approved by regulatory authorities for therapeutic use and is provided for compassionate use, outside of clinical trials, for the emergency treatment of individual patients with Covid-19 in serious condition and without valid therapeutic alternatives. "